Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Safety and Dose Evaluation Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral Idiopathic Parkinson's Disease (SUNRISE-PD)

NCT03720418 is registered in ClinicalTrials.gov with Sio Gene Therapies as lead sponsor.

NCT NCT03720418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03720418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Safety and Dose Evaluation Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral Idiopathic Parkinson's Disease (SUNRISE-PD)
Lead sponsor
Sio Gene Therapies
Phase
Phase 1/2
Overall status
Terminated
Start date
October 17, 2018
Completion date
April 12, 2022
Enrollment
6 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease